On June 5, 2022 Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, reported that yesterday on June 4, 2022, in the Industry Expert Theater during the ASCO (Free ASCO Whitepaper) 2022 conference, Dr. Marnix Bosch made a presentation discussing the Company’s DCVax-L technology for personalized dendritic cell vaccines, the Sawston, UK facility, the manufacturing technology, the development of automation, and preparations for manufacturing scale-up (Press release, Northwest Biotherapeutics, JUN 5, 2022, View Source [SID1234615615]). In addition, a video presentation about the DCVax-L clinical program was screened in the Company’s exhibit booth in the ASCO (Free ASCO Whitepaper) Exhibit Hall.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

These presentations are now available online at View Source

The Industry Expert Theater is not an official event of the ASCO (Free ASCO Whitepaper) Annual Meeting. It is not sponsored, endorsed or accredited by ASCO (Free ASCO Whitepaper), CancerLinq, or Conquer Cancer the ASCO (Free ASCO Whitepaper) Foundation. It is not CME-accredited.